COVID-19 Impact on Global Venous Thromboembolism Therapeutics Market Size, Status and Forecast 2020-2026

September 2020 | 92 pages | ID: C37CCABB5137EN
QYResearch

Abstracts

This report focuses on the global Venous Thromboembolism Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Venous Thromboembolism Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Johnson & Johnson
• Sanofi
• Boehringer Ingelheim
• Daiichi Sankyo
• Bristol-Myers Squibb (BMS)
• Bayer HealthCare
• Pfizer
• Leo Pharma
• Portola Pharmaceuticals
• ThromboGenics
• Ionis Pharmaceuticals
• GlycoMimetics
• BioInvent International

Market segment by Type, the product can be split into

• Factor Xa Inhibitors
• Direct Thrombin Inhibitors
• Heparin
• Vitamin K Antagonists
• Other

Market segment by Application, split into

• Hospital Pharmacies
• Retail Pharmacies
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Venous Thromboembolism Therapeutics status, future forecast, growth opportunity, key market and key players.
• To present the Venous Thromboembolism Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Venous Thromboembolism Therapeutics are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Venous Thromboembolism Therapeutics Revenue
1.4 Market Analysis by Type
  1.4.1 Global Venous Thromboembolism Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Factor Xa Inhibitors
  1.4.3 Direct Thrombin Inhibitors
  1.4.4 Heparin
  1.4.5 Vitamin K Antagonists
  1.4.6 Other
1.5 Market by Application
  1.5.1 Global Venous Thromboembolism Therapeutics Market Share by Application: 2020 VS 2026
  1.5.2 Hospital Pharmacies
  1.5.3 Retail Pharmacies
  1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): Venous Thromboembolism Therapeutics Industry Impact
  1.6.1 How the Covid-19 is Affecting the Venous Thromboembolism Therapeutics Industry
    1.6.1.1 Venous Thromboembolism Therapeutics Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Venous Thromboembolism Therapeutics Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Venous Thromboembolism Therapeutics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Venous Thromboembolism Therapeutics Market Perspective (2015-2026)
2.2 Venous Thromboembolism Therapeutics Growth Trends by Regions
  2.2.1 Venous Thromboembolism Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Venous Thromboembolism Therapeutics Historic Market Share by Regions (2015-2020)
  2.2.3 Venous Thromboembolism Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Venous Thromboembolism Therapeutics Market Growth Strategy
  2.3.6 Primary Interviews with Key Venous Thromboembolism Therapeutics Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Venous Thromboembolism Therapeutics Players by Market Size
  3.1.1 Global Top Venous Thromboembolism Therapeutics Players by Revenue (2015-2020)
  3.1.2 Global Venous Thromboembolism Therapeutics Revenue Market Share by Players (2015-2020)
  3.1.3 Global Venous Thromboembolism Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Venous Thromboembolism Therapeutics Market Concentration Ratio
  3.2.1 Global Venous Thromboembolism Therapeutics Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Venous Thromboembolism Therapeutics Revenue in 2019
3.3 Venous Thromboembolism Therapeutics Key Players Head office and Area Served
3.4 Key Players Venous Thromboembolism Therapeutics Product Solution and Service
3.5 Date of Enter into Venous Thromboembolism Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Venous Thromboembolism Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Venous Thromboembolism Therapeutics Forecasted Market Size by Type (2021-2026)

5 VENOUS THROMBOEMBOLISM THERAPEUTICS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Venous Thromboembolism Therapeutics Market Size by Application (2015-2020)
5.2 Global Venous Thromboembolism Therapeutics Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Venous Thromboembolism Therapeutics Market Size (2015-2020)
6.2 Venous Thromboembolism Therapeutics Key Players in North America (2019-2020)
6.3 North America Venous Thromboembolism Therapeutics Market Size by Type (2015-2020)
6.4 North America Venous Thromboembolism Therapeutics Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Venous Thromboembolism Therapeutics Market Size (2015-2020)
7.2 Venous Thromboembolism Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Venous Thromboembolism Therapeutics Market Size by Type (2015-2020)
7.4 Europe Venous Thromboembolism Therapeutics Market Size by Application (2015-2020)

8 CHINA

8.1 China Venous Thromboembolism Therapeutics Market Size (2015-2020)
8.2 Venous Thromboembolism Therapeutics Key Players in China (2019-2020)
8.3 China Venous Thromboembolism Therapeutics Market Size by Type (2015-2020)
8.4 China Venous Thromboembolism Therapeutics Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Venous Thromboembolism Therapeutics Market Size (2015-2020)
9.2 Venous Thromboembolism Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Venous Thromboembolism Therapeutics Market Size by Type (2015-2020)
9.4 Japan Venous Thromboembolism Therapeutics Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Venous Thromboembolism Therapeutics Market Size (2015-2020)
10.2 Venous Thromboembolism Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Venous Thromboembolism Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Venous Thromboembolism Therapeutics Market Size by Application (2015-2020)

11 INDIA

11.1 India Venous Thromboembolism Therapeutics Market Size (2015-2020)
11.2 Venous Thromboembolism Therapeutics Key Players in India (2019-2020)
11.3 India Venous Thromboembolism Therapeutics Market Size by Type (2015-2020)
11.4 India Venous Thromboembolism Therapeutics Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Venous Thromboembolism Therapeutics Market Size (2015-2020)
12.2 Venous Thromboembolism Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Venous Thromboembolism Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Venous Thromboembolism Therapeutics Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Johnson & Johnson
  13.1.1 Johnson & Johnson Company Details
  13.1.2 Johnson & Johnson Business Overview and Its Total Revenue
  13.1.3 Johnson & Johnson Venous Thromboembolism Therapeutics Introduction
  13.1.4 Johnson & Johnson Revenue in Venous Thromboembolism Therapeutics Business (2015-2020))
  13.1.5 Johnson & Johnson Recent Development
13.2 Sanofi
  13.2.1 Sanofi Company Details
  13.2.2 Sanofi Business Overview and Its Total Revenue
  13.2.3 Sanofi Venous Thromboembolism Therapeutics Introduction
  13.2.4 Sanofi Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.2.5 Sanofi Recent Development
13.3 Boehringer Ingelheim
  13.3.1 Boehringer Ingelheim Company Details
  13.3.2 Boehringer Ingelheim Business Overview and Its Total Revenue
  13.3.3 Boehringer Ingelheim Venous Thromboembolism Therapeutics Introduction
  13.3.4 Boehringer Ingelheim Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.3.5 Boehringer Ingelheim Recent Development
13.4 Daiichi Sankyo
  13.4.1 Daiichi Sankyo Company Details
  13.4.2 Daiichi Sankyo Business Overview and Its Total Revenue
  13.4.3 Daiichi Sankyo Venous Thromboembolism Therapeutics Introduction
  13.4.4 Daiichi Sankyo Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.4.5 Daiichi Sankyo Recent Development
13.5 Bristol-Myers Squibb (BMS)
  13.5.1 Bristol-Myers Squibb (BMS) Company Details
  13.5.2 Bristol-Myers Squibb (BMS) Business Overview and Its Total Revenue
  13.5.3 Bristol-Myers Squibb (BMS) Venous Thromboembolism Therapeutics Introduction
  13.5.4 Bristol-Myers Squibb (BMS) Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.5.5 Bristol-Myers Squibb (BMS) Recent Development
13.6 Bayer HealthCare
  13.6.1 Bayer HealthCare Company Details
  13.6.2 Bayer HealthCare Business Overview and Its Total Revenue
  13.6.3 Bayer HealthCare Venous Thromboembolism Therapeutics Introduction
  13.6.4 Bayer HealthCare Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.6.5 Bayer HealthCare Recent Development
13.7 Pfizer
  13.7.1 Pfizer Company Details
  13.7.2 Pfizer Business Overview and Its Total Revenue
  13.7.3 Pfizer Venous Thromboembolism Therapeutics Introduction
  13.7.4 Pfizer Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.7.5 Pfizer Recent Development
13.8 Leo Pharma
  13.8.1 Leo Pharma Company Details
  13.8.2 Leo Pharma Business Overview and Its Total Revenue
  13.8.3 Leo Pharma Venous Thromboembolism Therapeutics Introduction
  13.8.4 Leo Pharma Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.8.5 Leo Pharma Recent Development
13.9 Portola Pharmaceuticals
  13.9.1 Portola Pharmaceuticals Company Details
  13.9.2 Portola Pharmaceuticals Business Overview and Its Total Revenue
  13.9.3 Portola Pharmaceuticals Venous Thromboembolism Therapeutics Introduction
  13.9.4 Portola Pharmaceuticals Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.9.5 Portola Pharmaceuticals Recent Development
13.10 ThromboGenics
  13.10.1 ThromboGenics Company Details
  13.10.2 ThromboGenics Business Overview and Its Total Revenue
  13.10.3 ThromboGenics Venous Thromboembolism Therapeutics Introduction
  13.10.4 ThromboGenics Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  13.10.5 ThromboGenics Recent Development
13.11 Ionis Pharmaceuticals
  10.11.1 Ionis Pharmaceuticals Company Details
  10.11.2 Ionis Pharmaceuticals Business Overview and Its Total Revenue
  10.11.3 Ionis Pharmaceuticals Venous Thromboembolism Therapeutics Introduction
  10.11.4 Ionis Pharmaceuticals Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  10.11.5 Ionis Pharmaceuticals Recent Development
13.12 GlycoMimetics
  10.12.1 GlycoMimetics Company Details
  10.12.2 GlycoMimetics Business Overview and Its Total Revenue
  10.12.3 GlycoMimetics Venous Thromboembolism Therapeutics Introduction
  10.12.4 GlycoMimetics Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  10.12.5 GlycoMimetics Recent Development
13.13 BioInvent International
  10.13.1 BioInvent International Company Details
  10.13.2 BioInvent International Business Overview and Its Total Revenue
  10.13.3 BioInvent International Venous Thromboembolism Therapeutics Introduction
  10.13.4 BioInvent International Revenue in Venous Thromboembolism Therapeutics Business (2015-2020)
  10.13.5 BioInvent International Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Venous Thromboembolism Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Venous Thromboembolism Therapeutics Revenue
Table 3. Ranking of Global Top Venous Thromboembolism Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Venous Thromboembolism Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Factor Xa Inhibitors
Table 6. Key Players of Direct Thrombin Inhibitors
Table 7. Key Players of Heparin
Table 8. Key Players of Vitamin K Antagonists
Table 9. Key Players of Other
Table 10. COVID-19 Impact Global Market: (Four Venous Thromboembolism Therapeutics Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Venous Thromboembolism Therapeutics Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Venous Thromboembolism Therapeutics Players to Combat Covid-19 Impact
Table 15. Global Venous Thromboembolism Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Venous Thromboembolism Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Venous Thromboembolism Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Venous Thromboembolism Therapeutics Market Share by Regions (2015-2020)
Table 19. Global Venous Thromboembolism Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Venous Thromboembolism Therapeutics Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Venous Thromboembolism Therapeutics Market Growth Strategy
Table 25. Main Points Interviewed from Key Venous Thromboembolism Therapeutics Players
Table 26. Global Venous Thromboembolism Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 27. Global Venous Thromboembolism Therapeutics Market Share by Players (2015-2020)
Table 28. Global Top Venous Thromboembolism Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Venous Thromboembolism Therapeutics as of 2019)
Table 29. Global Venous Thromboembolism Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Venous Thromboembolism Therapeutics Product Solution and Service
Table 32. Date of Enter into Venous Thromboembolism Therapeutics Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Venous Thromboembolism Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 35. Global Venous Thromboembolism Therapeutics Market Size Share by Type (2015-2020)
Table 36. Global Venous Thromboembolism Therapeutics Revenue Market Share by Type (2021-2026)
Table 37. Global Venous Thromboembolism Therapeutics Market Size Share by Application (2015-2020)
Table 38. Global Venous Thromboembolism Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. Global Venous Thromboembolism Therapeutics Market Size Share by Application (2021-2026)
Table 40. North America Key Players Venous Thromboembolism Therapeutics Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Venous Thromboembolism Therapeutics Market Share (2019-2020)
Table 42. North America Venous Thromboembolism Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. North America Venous Thromboembolism Therapeutics Market Share by Type (2015-2020)
Table 44. North America Venous Thromboembolism Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. North America Venous Thromboembolism Therapeutics Market Share by Application (2015-2020)
Table 46. Europe Key Players Venous Thromboembolism Therapeutics Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Venous Thromboembolism Therapeutics Market Share (2019-2020)
Table 48. Europe Venous Thromboembolism Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Venous Thromboembolism Therapeutics Market Share by Type (2015-2020)
Table 50. Europe Venous Thromboembolism Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Venous Thromboembolism Therapeutics Market Share by Application (2015-2020)
Table 52. China Key Players Venous Thromboembolism Therapeutics Revenue (2019-2020) (Million US$)
Table 53. China Key Players Venous Thromboembolism Therapeutics Market Share (2019-2020)
Table 54. China Venous Thromboembolism Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. China Venous Thromboembolism Therapeutics Market Share by Type (2015-2020)
Table 56. China Venous Thromboembolism Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. China Venous Thromboembolism Therapeutics Market Share by Application (2015-2020)
Table 58. Japan Key Players Venous Thromboembolism Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Venous Thromboembolism Therapeutics Market Share (2019-2020)
Table 60. Japan Venous Thromboembolism Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Venous Thromboembolism Therapeutics Market Share by Type (2015-2020)
Table 62. Japan Venous Thromboembolism Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Venous Thromboembolism Therapeutics Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Venous Thromboembolism Therapeutics Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Venous Thromboembolism Therapeutics Market Share (2019-2020)
Table 66. Southeast Asia Venous Thromboembolism Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Venous Thromboembolism Therapeutics Market Share by Type (2015-2020)
Table 68. Southeast Asia Venous Thromboembolism Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Venous Thromboembolism Therapeutics Market Share by Application (2015-2020)
Table 70. India Key Players Venous Thromboembolism Therapeutics Revenue (2019-2020) (Million US$)
Table 71. India Key Players Venous Thromboembolism Therapeutics Market Share (2019-2020)
Table 72. India Venous Thromboembolism Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. India Venous Thromboembolism Therapeutics Market Share by Type (2015-2020)
Table 74. India Venous Thromboembolism Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. India Venous Thromboembolism Therapeutics Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Venous Thromboembolism Therapeutics Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Venous Thromboembolism Therapeutics Market Share (2019-2020)
Table 78. Central & South America Venous Thromboembolism Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Venous Thromboembolism Therapeutics Market Share by Type (2015-2020)
Table 80. Central & South America Venous Thromboembolism Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Venous Thromboembolism Therapeutics Market Share by Application (2015-2020)
Table 82. Johnson & Johnson Company Details
Table 83. Johnson & Johnson Business Overview
Table 84. Johnson & Johnson Product
Table 85. Johnson & Johnson Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 86. Johnson & Johnson Recent Development
Table 87. Sanofi Company Details
Table 88. Sanofi Business Overview
Table 89. Sanofi Product
Table 90. Sanofi Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 91. Sanofi Recent Development
Table 92. Boehringer Ingelheim Company Details
Table 93. Boehringer Ingelheim Business Overview
Table 94. Boehringer Ingelheim Product
Table 95. Boehringer Ingelheim Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 96. Boehringer Ingelheim Recent Development
Table 97. Daiichi Sankyo Company Details
Table 98. Daiichi Sankyo Business Overview
Table 99. Daiichi Sankyo Product
Table 100. Daiichi Sankyo Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 101. Daiichi Sankyo Recent Development
Table 102. Bristol-Myers Squibb (BMS) Company Details
Table 103. Bristol-Myers Squibb (BMS) Business Overview
Table 104. Bristol-Myers Squibb (BMS) Product
Table 105. Bristol-Myers Squibb (BMS) Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 106. Bristol-Myers Squibb (BMS) Recent Development
Table 107. Bayer HealthCare Company Details
Table 108. Bayer HealthCare Business Overview
Table 109. Bayer HealthCare Product
Table 110. Bayer HealthCare Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 111. Bayer HealthCare Recent Development
Table 112. Pfizer Company Details
Table 113. Pfizer Business Overview
Table 114. Pfizer Product
Table 115. Pfizer Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 116. Pfizer Recent Development
Table 117. Leo Pharma Business Overview
Table 118. Leo Pharma Product
Table 119. Leo Pharma Company Details
Table 120. Leo Pharma Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 121. Leo Pharma Recent Development
Table 122. Portola Pharmaceuticals Company Details
Table 123. Portola Pharmaceuticals Business Overview
Table 124. Portola Pharmaceuticals Product
Table 125. Portola Pharmaceuticals Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 126. Portola Pharmaceuticals Recent Development
Table 127. ThromboGenics Company Details
Table 128. ThromboGenics Business Overview
Table 129. ThromboGenics Product
Table 130. ThromboGenics Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 131. ThromboGenics Recent Development
Table 132. Ionis Pharmaceuticals Company Details
Table 133. Ionis Pharmaceuticals Business Overview
Table 134. Ionis Pharmaceuticals Product
Table 135. Ionis Pharmaceuticals Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 136. Ionis Pharmaceuticals Recent Development
Table 137. GlycoMimetics Company Details
Table 138. GlycoMimetics Business Overview
Table 139. GlycoMimetics Product
Table 140. GlycoMimetics Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 141. GlycoMimetics Recent Development
Table 142. BioInvent International Company Details
Table 143. BioInvent International Business Overview
Table 144. BioInvent International Product
Table 145. BioInvent International Revenue in Venous Thromboembolism Therapeutics Business (2015-2020) (Million US$)
Table 146. BioInvent International Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Venous Thromboembolism Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Factor Xa Inhibitors Features
Figure 3. Direct Thrombin Inhibitors Features
Figure 4. Heparin Features
Figure 5. Vitamin K Antagonists Features
Figure 6. Other Features
Figure 7. Global Venous Thromboembolism Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Hospital Pharmacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Other Case Studies
Figure 11. Venous Thromboembolism Therapeutics Report Years Considered
Figure 12. Global Venous Thromboembolism Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Venous Thromboembolism Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Venous Thromboembolism Therapeutics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Venous Thromboembolism Therapeutics Market Share by Players in 2019
Figure 17. Global Top Venous Thromboembolism Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Venous Thromboembolism Therapeutics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Venous Thromboembolism Therapeutics Revenue in 2019
Figure 19. North America Venous Thromboembolism Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Venous Thromboembolism Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Venous Thromboembolism Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Venous Thromboembolism Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Venous Thromboembolism Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Venous Thromboembolism Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Venous Thromboembolism Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Johnson & Johnson Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 28. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Sanofi Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 30. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Boehringer Ingelheim Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 32. Daiichi Sankyo Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Daiichi Sankyo Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 34. Bristol-Myers Squibb (BMS) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Bristol-Myers Squibb (BMS) Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 36. Bayer HealthCare Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Bayer HealthCare Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 38. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Pfizer Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 40. Leo Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Leo Pharma Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 42. Portola Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Portola Pharmaceuticals Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 44. ThromboGenics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. ThromboGenics Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 46. Ionis Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Ionis Pharmaceuticals Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 48. GlycoMimetics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. GlycoMimetics Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 50. BioInvent International Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. BioInvent International Revenue Growth Rate in Venous Thromboembolism Therapeutics Business (2015-2020)
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed